Almirall Posts Net Loss in FY21, Base EBITDA Up; Sees low EBITDA and core net sales growth in FY22

(RTTNews) – Almirall, SA (ALM), a Spanish biopharmaceutical company, announced on Monday that its net loss for the financial year 2021 was 40.9 million euros, mainly due to impairment charges.

Normalized net income amounted to 81.4 million euros compared to 95.1 million euros last year.

EBITDA slightly decreased by 1.1% compared to last year to 235.6 million euros. Core EBITDA, excluding AstraZeneca’s contribution, increased 17% year-on-year to €211.3 million. Strong operational performance was driven by the positive contribution from growth drivers and the strong performance of the EU Dermatology portfolio

Total revenue reached €836.5 million, up 2.7% from €814.5 million last year. Net sales increased by 2.5% to EUR 827.2 million, driven by the positive contribution from growth drivers and a strong performance in dermatology in the EU.

Base net sales reached €809.8 million, an increase of 7.2% year-on-year.

In addition, the company said that a proposed dividend of 0.19 euros per share will be submitted at the next annual general meeting on May 6. million euros to 210 million euros.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ann J. Cox